TendieTensor TendieTensor
You’re browsing as
Guest
Free Preview
Sign in/sign up to unlock all features.
Market News Page 1 of 234 • 5,848 articles
A Year of Market Fear — and Resilience: Breaking Down the VIX in 2025
Investing.com • Mike Zaccardi, Cfa, Cmt
A Year of Market Fear — and Resilience: Breaking Down the VIX in 2025

12/27/2025 01:31 AM • 2025 was marked by significant market volatility despite ending with resilience. The VIX spiked dramatically in April (above 60) following trade war rhetoric and policy uncertainty, but the S&P 500 recovered strongly with a 35%+ rally from May onward. Despite macro noise around tariffs, inflation, and Fed policy, the market delivered 15-20% returns with a maximum drawdown of only 19%, rewarding investors who focused on price action over headlines.

BACpS - Buffett trimmed the position by 26.3 million shares, suggesting a measured approach to the financial sector
AMJB - CEO Jamie Dimon's 'cockroaches' comment in October sparked renewed concerns about regional bank exposure to bad loans and triggered negative price action in the financial sector.
#VIX volatility #S&P 500 #trade war #Fed policy #market resilience #tariffs #corporate earnings #inflation #labor market
Read More
Is SynergyRx GLP-1 Legitimate? Platform Lists Compounded Semaglutide at $200 With Oral Tablet Options
GlobeNewswire Inc. • Not Specified
Is SynergyRx GLP-1 Legitimate? Platform Lists Compounded Semaglutide at $200 With Oral Tablet Options

12/26/2025 11:58 PM • SynergyRx, a telehealth platform, offers compounded semaglutide starting at $200/month and oral tablet alternatives for weight loss medication. The platform maintains LegitScript certification and publishes provider credentials, but compounded medications lack FDA approval as finished products. The article emphasizes regulatory scrutiny in the GLP-1 telehealth industry and advises consumers to consult healthcare providers before starting treatment.

BACpP - Buffett trimmed the position by 26.3 million shares, suggesting a measured approach to the financial sector
SNYR - The article presents SynergyRx factually, highlighting both legitimacy indicators (LegitScript certification, published provider credentials, transparent pricing) and significant caveats (compounded medications lack FDA approval, regulatory scrutiny in the industry, prescription not guaranteed). The balanced presentation with extensive disclaimers and emphasis on consumer caution prevents a positive sentiment, while the documented operational transparency and verification signals prevent a negative sentiment.
#GLP-1 medications #telehealth #semaglutide #tirzepatide #weight loss #compounded medications #FDA-approved drugs #regulatory compliance #pricing transparency
Read More
Direct Meds GLP-1 Medications Platform Maintains LegitScript Certification as New Year Weight Loss Interest Peaks Amid Compounding Regulatory Shifts
GlobeNewswire Inc. • Not Specified
Direct Meds GLP-1 Medications Platform Maintains LegitScript Certification as New Year Weight Loss Interest Peaks Amid Compounding Regulatory Shifts

12/26/2025 11:34 PM • Direct Meds, a LegitScript-certified telehealth platform, continues facilitating access to compounded semaglutide and tirzepatide through licensed providers as the weight loss medication market experiences regulatory changes. The platform operates with independent healthcare providers and 503A compounding pharmacies, though compounded medications remain non-FDA-approved and carry serious safety risks including potential thyroid C-cell tumors.

BACpQ - Buffett trimmed the position by 26.3 million shares, suggesting a measured approach to the financial sector
NVO - Mentioned only as the manufacturer of FDA-approved Ozempic and Wegovy. The article notes that Direct Meds is not affiliated with or endorsed by Novo Nordisk. The mention is contextual rather than substantive to the main narrative.
#GLP-1 medications #telehealth #compounded semaglutide #compounded tirzepatide #weight loss #regulatory compliance #LegitScript certification #FDA shortage resolution #503A compounding pharmacies
Read More
Global Times 2025 Yearender: China shares opportunities, growth dividends as an empowering country
GlobeNewswire Inc. • Global Times
Global Times 2025 Yearender: China shares opportunities, growth dividends as an empowering country

12/26/2025 08:35 PM • China is positioning itself as a 'global enabling power' through robotics, space exploration, and infrastructure projects that share technological benefits with developing nations. Chinese-made service robots are being deployed in Saudi Arabia's healthcare sector, while China's space program includes partnerships with Pakistan for astronaut training. Infrastructure projects like Vietnam's Hanoi Light Rail demonstrate how Chinese investments improve connectivity and living standards for local populations.

BACpO - Buffett trimmed the position by 26.3 million shares, suggesting a measured approach to the financial sector
BABA - Cited alongside DeepSeek as a Chinese company developing advanced and highly efficient open-source AI systems, contributing to China's technological achievements that benefit developing nations.
#Chinese robotics #space exploration #infrastructure development #Belt and Road Initiative #AI technology #developing countries #international cooperation #technology transfer
Read More
Best Semaglutide Options for 2026: New Oral Wegovy Pill Approved by FDA as Patients Compare Injectable and Compounded Access Pathways
GlobeNewswire Inc. • Not Specified
Best Semaglutide Options for 2026: New Oral Wegovy Pill Approved by FDA as Patients Compare Injectable and Compounded Access Pathways

12/26/2025 06:48 PM • The FDA approved Novo Nordisk's oral Wegovy pill (25 mg) on December 22, 2025, marking the first FDA-approved oral GLP-1 therapy for chronic weight management. The approval expands patient options beyond injectable Wegovy and compounded semaglutide alternatives. The oral formulation showed approximately 13-14% average weight loss in clinical trials and is expected to launch in early January 2026 at approximately $149/month for starting doses. Compounded semaglutide remains available through telehealth platforms like MEDVi at lower costs ($179 first month) but lacks FDA approval as a finished product.

BACpM - Buffett trimmed the position by 26.3 million shares, suggesting a measured approach to the financial sector
NVO - FDA approval of oral Wegovy pill represents a significant regulatory milestone and market expansion. The new formulation adds an FDA-approved oral pathway for weight management, potentially capturing market share from compounded alternatives and expanding the addressable patient population through improved accessibility and convenience of daily oral dosing versus weekly injections.
#semaglutide #GLP-1 #Wegovy #FDA approval #weight loss medication #oral formulation #compounded medications #telehealth #weight management #injectable vs oral
Read More
Down 73% From All-Time High, Is The Trade Desk Stock a Buy?
The Motley Fool • Daniel Sparks
Down 73% From All-Time High, Is The Trade Desk Stock a Buy?

12/26/2025 06:31 PM • The Trade Desk stock has plummeted 73% from its all-time high, though the underlying business remains solid with 18% year-over-year revenue growth and strong profitability (43% EBITDA margin). However, growth is decelerating from prior quarters, and the stock still trades at a premium 44 P/E ratio compared to the S&P 500's 26. The analyst suggests waiting for either a $30 price target or evidence of growth reacceleration before buying.

BACpN - Buffett trimmed the position by 26.3 million shares, suggesting a measured approach to the financial sector
TTD - While the company demonstrates solid fundamentals with strong profitability (16% net margin, 43% EBITDA margin), 95%+ customer retention, and continued revenue growth (18% YoY), the stock faces headwinds from decelerating growth (from 25% in Q1 to 13% expected in Q4), a premium valuation (44 P/E vs S&P 500's 26), and management's admission of Q4 2024 underperformance. The analyst remains on the sidelines, suggesting the risk-reward is not yet favorable.
#programmatic advertising #CTV (Connected TV) #growth deceleration #valuation #profitability #customer retention
Read More
MEDIROM Partners with World
GlobeNewswire Inc. • Globe Newswire
MEDIROM Partners with World

12/26/2025 05:55 PM • MEDIROM Healthcare Technologies Inc. has entered into a Master Service Agreement with Tools for Humanity and World Foundation to deploy 'Proof of Human' verification technology across Japan. The collaboration leverages MEDIROM's network of approximately 300 physical locations to establish verification services, including Orbs camera installations and flagship locations. The initiative is expected to generate new revenue streams through operation fees while contributing to digital trust infrastructure in Japan.

BACpK - Buffett trimmed the position by 26.3 million shares, suggesting a measured approach to the financial sector
MRM - The company is expanding into a new revenue-generating business segment through a strategic partnership with established technology firms. The collaboration leverages existing infrastructure (300 locations) to deploy emerging technology, positioning MEDIROM as a key player in digital trust infrastructure. The initiative is expected to contribute to revenue growth and support the company's evolution as a health tech company.
#Proof of Human #World ID #blockchain technology #AI verification #digital infrastructure #healthcare technology #Japan expansion #Sam Altman #Tools for Humanity
Read More
Southpoint holdings in Fennec Pharmaceuticals Inc. (TSX: FENC)
GlobeNewswire Inc. • Na
Southpoint holdings in Fennec Pharmaceuticals Inc. (TSX: FENC)

12/26/2025 05:44 PM • Southpoint Capital Advisors sold 1 million common shares (2.93%) of Fennec Pharmaceuticals on December 24, 2025, at USD $7.50 per share. The firm retains control of 2.7 million shares (approximately 8% of outstanding shares on a fully diluted basis) and may adjust its position based on market conditions.

BACpL - Buffett trimmed the position by 26.3 million shares, suggesting a measured approach to the financial sector
FENC - The sale itself is a neutral event as it reflects a portfolio rebalancing by a major shareholder rather than a negative assessment of the company. Southpoint's retention of 8% ownership and the stated investment purpose indicate continued confidence in Fennec's prospects.
#share sale #stake reduction #investment disposition #pharmaceutical company #beneficial ownership
Read More
Class Action Filed Against Coupang, Inc. (CPNG) - February 17, 2026 Deadline to Join – Contact Levi & Korsinsky
GlobeNewswire Inc. • Levi & Korsinsky, Llp
Class Action Filed Against Coupang, Inc. (CPNG) - February 17, 2026 Deadline to Join – Contact Levi & Korsinsky

12/26/2025 04:58 PM • Levi & Korsinsky has filed a class action securities lawsuit against Coupang, Inc. alleging the company made false statements regarding inadequate cybersecurity protocols that allowed a former employee to access sensitive customer information for nearly six months without detection. The complaint further alleges that defendants failed to properly report the data breach in SEC filings. Investors who suffered losses between August 6, 2025 and December 16, 2025 have until February 17, 2026 to join the lawsuit.

BMY - Mentioned as a strategic collaboration partner with no specific details provided
CPNG - The company faces serious allegations of securities fraud, inadequate cybersecurity protocols, unauthorized data access by a former employee, and failure to properly disclose the breach to the SEC. These violations expose the company to significant legal, regulatory, and financial risks.
#class action lawsuit #securities fraud #data breach #cybersecurity #SEC filing #investor losses
Read More
DeFi Technologies Sued for Securities Law Violations – Investors Should Contact Levi & Korsinsky Before January 30, 2026 to Discuss Your Rights – DEFT
GlobeNewswire Inc. • Levi & Korsinsky, Llp
DeFi Technologies Sued for Securities Law Violations – Investors Should Contact Levi & Korsinsky Before January 30, 2026 to Discuss Your Rights – DEFT

12/26/2025 04:58 PM • Levi & Korsinsky has filed a class action securities lawsuit against DeFi Technologies (NASDAQ: DEFT) alleging the company made false statements about its DeFi arbitrage strategy, understated competitive pressures, and was unlikely to meet its 2025 revenue guidance. Investors who suffered losses between May 12, 2025 and November 14, 2025 can join the lawsuit by January 30, 2026 with no out-of-pocket costs.

ALPMY - Mentioned as a strategic collaboration partner with no specific details provided
DEFT - The company is facing a securities fraud class action lawsuit alleging material misstatements regarding its core DeFi arbitrage strategy, competitive position, and inability to meet revenue guidance. These allegations indicate serious operational and disclosure failures that have negatively impacted investor value.
#securities fraud #class action lawsuit #DeFi arbitrage strategy #revenue guidance #false statements #investor losses
Read More
Levi & Korsinsky Announces the Filing of a Securities Class Action on Behalf of Blue Owl Capital Inc.(OWL) Shareholders
GlobeNewswire Inc. • Levi & Korsinsky, Llp
Levi & Korsinsky Announces the Filing of a Securities Class Action on Behalf of Blue Owl Capital Inc.(OWL) Shareholders

12/26/2025 04:57 PM • Law firm Levi & Korsinsky has filed a securities class action lawsuit against Blue Owl Capital Inc. on behalf of shareholders who suffered losses between February 6, 2025 and November 16, 2025. The complaint alleges the company made false statements and concealed material information regarding redemption pressures, undisclosed liquidity issues, and potential restrictions on business development company redemptions. Investors have until February 2, 2026 to request lead plaintiff status.

OWL - The company is the subject of a securities fraud class action lawsuit alleging false statements, concealment of material information regarding liquidity issues, and redemption pressures. These allegations indicate serious corporate governance and disclosure failures that negatively impact shareholder value.
#securities fraud #class action lawsuit #Blue Owl Capital Inc. #redemptions #liquidity issues #shareholder losses #material misstatement
Read More
Telix Pharmaceuticals Ltd. Securities Fraud Class Action Lawsuit Pending: Contact Levi & Korsinsky Before January 9, 2026 to Discuss Your Rights – TLX
GlobeNewswire Inc. • Levi & Korsinsky, Llp
Telix Pharmaceuticals Ltd. Securities Fraud Class Action Lawsuit Pending: Contact Levi & Korsinsky Before January 9, 2026 to Discuss Your Rights – TLX

12/26/2025 04:57 PM • Levi & Korsinsky, LLP has filed a class action securities lawsuit against Telix Pharmaceuticals Ltd. for alleged securities fraud between February 21, 2025 and August 28, 2025. The complaint alleges that defendants made false statements about prostate cancer therapeutic progress, overstated supply chain quality, and made materially misleading statements about business operations. Investors have until January 9, 2026 to request lead plaintiff status.

MRNA - Mentioned as a strategic collaboration partner with no specific details provided
TLX - The company is the subject of a securities fraud class action lawsuit alleging material misstatements about therapeutic progress, supply chain quality, and business operations. This represents significant legal and reputational risk to investors.
#securities fraud #class action lawsuit #false statements #prostate cancer therapeutics #supply chain #investor losses #lead plaintiff
Read More
Levi & Korsinsky Reminds Perrigo Company plc Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of January 16, 2026 – PRGO
GlobeNewswire Inc. • Levi & Korsinsky, Llp
Levi & Korsinsky Reminds Perrigo Company plc Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of January 16, 2026 – PRGO

12/26/2025 04:57 PM • A class action securities lawsuit has been filed against Perrigo Company plc for alleged securities fraud between February 27, 2023 and November 4, 2025. The complaint alleges that defendants made false statements about the infant formula business acquired from Nestlé, including concealing significant underinvestment, manufacturing deficiencies, and the need for substantial capital expenditures. The lead plaintiff deadline is January 16, 2026.

REGN - Mentioned as a strategic collaboration partner with no specific details provided
PRGO - The company is the subject of a securities fraud class action lawsuit alleging false statements about its infant formula business, including concealed underinvestment, manufacturing deficiencies, and overstated financial results. These allegations represent serious legal and reputational risks.
#class action lawsuit #securities fraud #Perrigo Company plc #infant formula business #Nestlé acquisition #manufacturing deficiencies #financial misstatement #lead plaintiff deadline
Read More
StubHub Holdings, Inc. Sued for Securities Law Violations – Investors Should Contact Levi & Korsinsky for More Information – STUB
GlobeNewswire Inc. • Levi & Korsinsky, Llp
StubHub Holdings, Inc. Sued for Securities Law Violations – Investors Should Contact Levi & Korsinsky for More Information – STUB

12/26/2025 04:57 PM • Levi & Korsinsky, LLP has filed a class action securities lawsuit against StubHub Holdings, Inc. for alleged securities fraud related to its September 2025 IPO. The complaint alleges the company made false statements about vendor payment timing changes that materially impacted free cash flow and misled investors about business prospects. Investors who purchased stock during the IPO have until January 23, 2026 to request lead plaintiff status.

CELGr - Mentioned as a strategic collaboration partner with no specific details provided
STUB - The company is facing a securities fraud lawsuit alleging false statements and concealment of material information regarding vendor payment timing and free cash flow impacts, which directly harms investor confidence and stock value.
#securities fraud #class action lawsuit #IPO #free cash flow #vendor payments #misleading statements
Read More
Lost Money on Avantor, Inc.(AVTR)? Join Class Action Suit Seeking Recovery – Contact Levi & Korsinsky
GlobeNewswire Inc. • Levi & Korsinsky, Llp
Lost Money on Avantor, Inc.(AVTR)? Join Class Action Suit Seeking Recovery – Contact Levi & Korsinsky

12/26/2025 04:56 PM • Levi & Korsinsky, LLP has filed class action securities lawsuits against Avantor, Inc. (AVTR), Coupang, Inc. (CPNG), and DeFi Technologies (DEFT) alleging securities fraud. Avantor investors claim the company made false statements about its competitive positioning and concealed negative effects from increased competition during March 5, 2024 to October 28, 2025. Investors who suffered losses during the relevant periods can join the lawsuits at no cost.

BACpE - Buffett trimmed the position by 26.3 million shares, suggesting a measured approach to the financial sector
AVTR - Company is subject to securities fraud allegations involving false statements about competitive positioning and concealment of negative competitive effects, resulting in investor losses.
#class action lawsuit #securities fraud #investor losses #false statements #competitive positioning #lead plaintiff deadline
Read More
Levi & Korsinsky Reminds Stride, Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of January 12, 2026 – LRN
GlobeNewswire Inc. • Levi & Korsinsky, Llp
Levi & Korsinsky Reminds Stride, Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of January 12, 2026 – LRN

12/26/2025 04:56 PM • A class action securities lawsuit has been filed against Stride, Inc. (LRN) alleging securities fraud between October 22, 2024 and October 28, 2025. The complaint claims Stride inflated enrollment numbers, cut staffing costs beyond statutory limits, ignored compliance requirements including background checks and special education services, suppressed whistleblowers, and lost enrollments. Investors have until January 12, 2026 to request lead plaintiff status.

BACpB - Buffett trimmed the position by 26.3 million shares, suggesting a measured approach to the financial sector
LRN - The company faces serious allegations of securities fraud including inflating enrollment numbers, violating staffing requirements, ignoring compliance and special education mandates, suppressing whistleblowers, and losing enrollments. These allegations represent significant operational, legal, and financial risks.
#class action lawsuit #securities fraud #enrollment inflation #ghost students #staffing violations #compliance violations #whistleblower suppression #lead plaintiff deadline
Read More
Levi & Korsinsky Announces the Filing of a Securities Class Action on Behalf of Integer Holdings Corporation (ITGR) Shareholders
GlobeNewswire Inc. • Levi & Korsinsky, Llp
Levi & Korsinsky Announces the Filing of a Securities Class Action on Behalf of Integer Holdings Corporation (ITGR) Shareholders

12/26/2025 04:56 PM • Levi & Korsinsky has filed a securities class action lawsuit against Integer Holdings Corporation on behalf of shareholders who suffered losses between July 25, 2024 and October 22, 2025. The complaint alleges that Integer made false statements about its competitive position in the electrophysiology manufacturing market, overstated customer demand visibility, and mischaracterized electrophysiology devices as a growth driver. Investors have until February 9, 2026 to request lead plaintiff status.

BAC - Buffett trimmed the position by 26.3 million shares, suggesting a measured approach to the financial sector
ITGR - The company is the subject of a securities fraud class action lawsuit alleging material misstatements about its competitive position, customer demand visibility, and product growth prospects in the electrophysiology market. These allegations indicate significant operational and disclosure failures that resulted in shareholder losses.
#securities fraud #class action lawsuit #electrophysiology devices #false statements #shareholder losses #cardio & vascular segment
Read More
DexCom, Inc. Sued for Securities Law Violations – Investors Should Contact Levi & Korsinsky Before December 26, 2025 to Discuss Your Rights – DXCM
GlobeNewswire Inc. • Levi & Korsinsky, Llp
DexCom, Inc. Sued for Securities Law Violations – Investors Should Contact Levi & Korsinsky Before December 26, 2025 to Discuss Your Rights – DXCM

12/26/2025 04:56 PM • DexCom faces a class action securities lawsuit alleging the company made unauthorized design changes to its G6 and G7 glucose monitoring devices without FDA approval, rendering them less reliable and presenting health risks to users. The complaint claims defendants overstated the devices' enhancements and concealed the true scope of issues, exposing the company to regulatory scrutiny and significant financial harm. Investors who suffered losses between January 8, 2024 and September 17, 2025 can join the lawsuit.

DXCM - The company faces serious allegations of securities fraud, unauthorized product design changes, FDA violations, and concealment of health risks associated with its medical devices. These factors pose significant legal, regulatory, and reputational risks that negatively impact investor confidence and shareholder value.
#securities fraud #class action lawsuit #glucose monitoring devices #FDA violations #product reliability #investor losses
Read More
You Don’t Need Big Money for These 3 Under-$30 Stock Plays
Investing.com • Chris Markoch
You Don’t Need Big Money for These 3 Under-$30 Stock Plays

12/26/2025 02:45 PM • The article highlights three under-$30 stocks suitable for investors with limited capital: Nintendo (NTDOY), which faces RAM cost pressures but maintains strong Switch 2 sales forecasts; NU Holdings (NU), a Latin American fintech showing 61% YTD growth with expansion plans; and Carnival Cruise Lines (CCL), which has recovered with 21% YTD gains and reinstated its dividend.

AMGN - Mentioned as a strategic collaboration partner with no specific details provided
NTDOY - Despite recent 21.7% decline due to RAM cost pressures, the company increased Switch 2 sales forecast from 15M to 19M units and maintains current pricing through supplier contracts. Stock trades under $20, presenting a bargain opportunity if sales targets are met.
#under-$30 stocks #low-priced stocks #growth potential #Nintendo Switch 2 #fintech #cruise lines #dividend reinstatement
Read More
Fitell Corporation Announces Interim Dividend and Shareholder Loyalty Program
GlobeNewswire Inc. • Not Specified
Fitell Corporation Announces Interim Dividend and Shareholder Loyalty Program

12/26/2025 01:58 PM • Fitell Corporation announced an interim dividend of $0.10 per share payable January 13, 2026, and a one-time shareholder loyalty program offering up to $0.15 per share in three tranches for shareholders who maintain book-entry ownership for 30-90 days. The initiatives reflect the company's improved cash position and commitment to returning value to shareholders while supporting growth in fitness, corporate treasury management, and robotics ventures.

FTEL - The company is returning capital to shareholders through both an interim dividend and a loyalty program, indicating improved financial health and cash position. Management expressed confidence in the balance sheet and operational outlook, and the company is expanding into new growth areas including robotics ventures.
#interim dividend #shareholder loyalty program #book-entry transfer #capital return #fitness equipment #robotics joint-venture #2F Robotics
Read More
Microsoft Faces a Key Question: Compounder at Any Price or Accumulate Slowly
Investing.com • Itai Smidt
Microsoft Faces a Key Question: Compounder at Any Price or Accumulate Slowly

12/26/2025 01:48 PM • Microsoft trades at $486.72 with a P/E of 34.65, priced as a premium compounder. The company shows strong fundamentals with 18.43% revenue growth, 25.15% EPS growth, and 35.72% net margins. However, the valuation depends on three critical pillars: AI CapEx normalization by FY2028, continued Azure/AI growth at high double digits, and monetization of OpenAI/Anthropic relationships. Material risks include potential AI infrastructure overbuild, competition from Google and Amazon, and OpenAI financing/governance risks. Despite these risks, the analyst rates MSFT as a Buy given its strong financial performance and structural advantages.

MSFT - Strong financial metrics (18%+ revenue growth, 25%+ EPS growth, 35%+ net margins, 20%+ return on capital) and strategic positioning in AI/cloud with Azure growing at 39%. Analyst rates as Buy despite premium valuation. Positive outlook contingent on successful AI CapEx deployment and continued market dominance.
#Microsoft #AI infrastructure #Azure #valuation #CapEx #OpenAI #cloud computing #earnings growth #competitive risks
Read More
DEADLINE ALERT for FCX, PRGO, JYD, STUB: Law Offices of Howard G. Smith Reminds Investors of Opportunity to Lead Securities Fraud Class Actions
GlobeNewswire Inc. • Law Offices Of Howard G. Smith
DEADLINE ALERT for FCX, PRGO, JYD, STUB: Law Offices of Howard G. Smith Reminds Investors of Opportunity to Lead Securities Fraud Class Actions

12/26/2025 12:56 PM • Law Offices of Howard G. Smith has announced securities fraud class action lawsuits against four publicly-traded companies: Freeport-McMoRan (FCX) for safety issues at its Indonesian mine, Perrigo Company (PRGO) for undisclosed problems with its acquired infant formula business, Jayud Global Logistics (JYD) for involvement in a fraudulent stock promotion scheme, and StubHub Holdings (STUB) for misleading cash flow reporting. Investors have until January 2026 to file lead plaintiff motions.

FCX - Company faces securities fraud allegations for failing to disclose inadequate safety measures at its Grasberg mine in Indonesia, creating undisclosed regulatory and reputational risks.
#securities fraud #class action lawsuit #lead plaintiff deadline #false statements #misleading disclosures #investor losses
Read More
Deadline Alert: CarMax, Inc. (KMX) Shareholders Who Lost Money Urged To Contact Glancy Prongay & Murray LLP About Securities Fraud Lawsuit
GlobeNewswire Inc. • Glancy Prongay & Murray Llp
Deadline Alert: CarMax, Inc. (KMX) Shareholders Who Lost Money Urged To Contact Glancy Prongay & Murray LLP About Securities Fraud Lawsuit

12/26/2025 12:49 PM • CarMax faces a securities fraud class action lawsuit after the company disclosed significant revenue and profit declines in Q2 2026 results on September 25, 2025. The lawsuit alleges CarMax made materially false statements about growth prospects, which were allegedly driven by temporary tariff-related speculation rather than sustainable business fundamentals. The stock fell 20.1% following the disclosure. Investors have until January 2, 2026 to file a lead plaintiff motion.

PIPR - Mentioned as conference host facilitating investor interactions
KMX - CarMax disclosed significant financial deterioration (6% revenue decline, 7.2% retail vehicle revenue decline, 5.6% gross profit decline) and faces securities fraud allegations for allegedly overstating growth prospects. The stock experienced a sharp 20.1% decline on the news, and the company is accused of misleading investors about the sustainability of its earlier growth.
#securities fraud #class action lawsuit #revenue decline #misleading statements #tariff speculation #inventory right-sizing #loan loss provisions
Read More
Silver Jumps 6%, Platinum Up 8%, Palladium Up 11% As Metal Shock Erupts: What's Moving Markets Friday?
Benzinga • Piero Cingari
Silver Jumps 6%, Platinum Up 8%, Palladium Up 11% As Metal Shock Erupts: What's Moving Markets Friday?

12/26/2025 12:47 PM • Precious and industrial metals surged on December 26, 2025, with silver up 6% to $76/oz, platinum up 8%, and palladium up 11%, driven by supply crunches in Asian markets. Silver and platinum are on track for their best years since 1978 and on record, respectively. Gold rose 1.3% to $4,550/oz while copper climbed 4.6%. Among equities, copper producer Freeport-McMoRan led gains at +3%, while the S&P 500 remained flat near 5,930 points.

FCX - Copper producer led S&P 500 gainers with +3% gain, benefiting from copper's 4.6% climb as it recovers from July selloff.
#precious metals #silver #platinum #palladium #supply crunch #copper #gold #market volatility #year-to-date gains
Read More
Eli Lilly’s New Drug Data Sets Up a High-Stakes 2026
Investing.com • Leo Miller
Eli Lilly’s New Drug Data Sets Up a High-Stakes 2026

12/26/2025 12:44 PM • Eli Lilly released promising clinical trial data for two next-generation weight loss and diabetes drugs in late 2025. Orforglipron, an oral GLP-1 pill, showed patients maintained 80-95% of weight loss when switching from injectables. Retatrutide demonstrated superior weight loss (28.7% vs 20.2% for current drugs) but had higher discontinuation rates. The company faces critical FDA approval decisions and additional trial readouts in 2026 that could significantly impact its stock performance.

LLY - Company demonstrated strong clinical trial results for next-generation drugs with potential to expand market reach through oral formulations and superior weight loss efficacy. Stock gained 71% year-to-date and company achieved $1 trillion market cap. However, sentiment is tempered by execution risks including FDA approval uncertainty and elevated discontinuation rates in retatrutide trials.
#weight loss drugs #GLP-1 medications #orforglipron #retatrutide #clinical trial data #FDA approval #pharmaceutical innovation #tirzepatide #Zepbound #Mounjaro
Read More